Drug Profile
Palopegteriparatide - Ascendis Pharma
Alternative Names: ACP 014; TransCon parathyroid hormone; TransCon PTH - Ascendis Pharma; TransCon PTH low-dose pen; TransCon™ PTH; YORVIPATHLatest Information Update: 18 Feb 2024
Price :
$50
*
At a glance
- Originator Ascendis Pharma
- Developer Ascendis Pharma; VISEN Pharmaceuticals
- Class Calcium regulators; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypoparathyroidism
Most Recent Events
- 31 Jan 2024 Preregistration for Hypoparathyroidism (Treatment-experienced) in United Kingdom (SC) (YORVIPATH® (9409007)
- 31 Jan 2024 Launched for Hypoparathyroidism (Treatment-experienced) in Germany, Austria (SC)
- 08 Jan 2024 Ascendis Pharma and Vector Pharma enter into a distribution agreement to commercialize Yorvipath™ in the Gulf Cooperation Council (GCC) countries